News

New Ovia Health Report Highlights Growing Demand for Family-Friendly Workplace Benefits in the U.S.

A recent report released by Ovia Health by Labcorp, titled “Future of Family Friendly 2024: Benefits That Matter,” offers insights into the preferences of U.S. workers regarding family-friendly workplace benefits. “This report indicates we are witnessing a shift in what employees seek in terms of family-friendly benefits, and they’re willing to change employers to find them,” said Jenny Carillo, Ph.D., President of Ovia.…

Villie Secures $700K in Pre-Seed Funding to Enhance Support for Expecting Parents

Villie, an online platform founded in 2021 by Kimberly Jolasun, has recently announced a significant milestone with the successful completion of a $700K pre-seed funding round. This investment round saw participation from prominent investors including XRC Labs, TxO by a16z, and Fearless Fund. The platform, conceptualized by Jolasun, aims to provide a supportive environment for expecting parents, facilitating connections and offering resources…

Lisa Health Study Unveils Workplace Realities: Menopause’s Impact on Women’s Careers

SRI (formerly Stanford Research Institute) and Lisa Health, the company behing the Midday menopause app, recently published a study shedding light on the often-overlooked challenges faced by menopausal women in the workforce. The study, conducted across the United States with 351 working women aged 40–65, aimed to understand the intersection of menopause and professional life. “There is a notable gap between desired…

Cosm Medical Receives FDA Clearance for Gynethotics Pessaries, Leading the Way in Personalized Pelvic Care

Cosm Medical, a Toronto-based company, has announced its recent FDA clearance for Gynethotics Pessaries, marking a significant milestone in pelvic care. This clearance, following closely on the heels of Health Canada approval, highlights Cosm’s dedication to improving patient outcomes and transforming treatment options for women globally. Gynethotics Pessaries represent a breakthrough in personalized pelvic care, setting a new standard in the field.…

Gynica Commences First-in-Human Clinical Trial for Novel IntraVag Treatment for Endometriosis

Gynica, a clinical-stage biotech startup focused on women’s health, has announced the initiation of a first-in-human Phase 1 clinical trial for a novel Endometriosis treatment. Led by renowned expert Prof. Felice Petraglia, the study aims to evaluate Gynica’s non-hormonal, intra-vaginal drug candidates using the IntraVag intra-vaginal drug delivery platform. Endometriosis, affecting over 200 million women worldwide, is characterized by the abnormal growth…

What’s New in Femtech This Week? (March 14, 2024)

Every Thursday we send out a curated newsletter on all things femtech and women’s health innovation. This is an excerpt from the latest edition. If you’d like to subscribe, you can do so at the bottom of this page. Highlights Rosy expands services to address women’s health beyond sexual wellness. Vini Mini raises €500K in seed funding to prevent food allergies in children. 23andMe launches new genetic…

Rosy Expands Services to Address Women’s Health Beyond Sexual Wellness

In a strategic move to broaden its scope, Rosy, led by Dr. Lyndsey Harper, is expanding its platform beyond sexual wellness to encompass various aspects of women’s health. This expansion targets areas such as endometriosis, fibroids, menopause, migraines, and more, aiming to provide comprehensive support for women across all stages of life. Rosy’s initiative is rooted in the recognition of unmet needs…

23andMe Launches New Genetic Reports on Breast Cancer Risk

23andMe has recently unveiled an initiative aimed at offering deeper insights into the risk of developing breast cancer. The company’s new genetic reports bring forth a new approach to cancer risk prediction, particularly focusing on breast, colorectal, and prostate cancer. Recent studies have underscored a concerning trend: a notable increase in cancer diagnoses among younger individuals. Federal data from the US indicates…